Bio Path: Up on U.S. patent for potential cancer therapy

Bio Path Holdings

22/10/2020 16:55

** Biotech firm's  BPTH.O  shares surge 38% to $5.7; set for
their best day in more than 1.5 years
    ** Stock among top pct gainer across U.S. exchanges 
    ** U.S. Patent and Trademark Office grants patent to
company's lead candidate, prexigebersen, to treat different
types of cancer in combination with front-line therapies
 urn:newsml:reuters.com:*:nGNXq6D3R
    ** Prexigebersen is currently in a mid-stage trial in
combination with chemotherapy drug, decitabine, as a treatment
for acute myeloid leukemia
    ** Stock has fallen ~30% YTD

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))